Immune imprinting in early life shapes cross-reactivity to influenza B virus haemagglutinin
- PMID: 38890491
- DOI: 10.1038/s41564-024-01732-8
Immune imprinting in early life shapes cross-reactivity to influenza B virus haemagglutinin
Abstract
Influenza exposures early in life are believed to shape future susceptibility to influenza infections by imprinting immunological biases that affect cross-reactivity to future influenza viruses. However, direct serological evidence linked to susceptibility is limited. Here we analysed haemagglutination-inhibition titres in 1,451 cross-sectional samples collected between 1992 and 2020, from individuals born between 1917 and 2008, against influenza B virus (IBV) isolates from 1940 to 2021. We included testing of 'future' isolates that circulated after sample collection. We show that immunological biases are conferred by early life IBV infection and result in lineage-specific cross-reactivity of a birth cohort towards future IBV isolates. This translates into differential estimates of susceptibility between birth cohorts towards the B/Yamagata and B/Victoria lineages, predicting lineage-specific birth-cohort distributions of observed medically attended IBV infections. Our data suggest that immunological measurements of imprinting could be important in modelling and predicting virus epidemiology.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.J Infect Dis. 2017 Dec 27;217(1):3-11. doi: 10.1093/infdis/jix546. J Infect Dis. 2017. PMID: 29294018 Free PMC article.
-
Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.Virus Res. 2020 Feb;277:197839. doi: 10.1016/j.virusres.2019.197839. Epub 2019 Dec 16. Virus Res. 2020. PMID: 31837382 Clinical Trial.
-
H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.mBio. 2020 Dec 15;11(6):e02090-20. doi: 10.1128/mBio.02090-20. mBio. 2020. PMID: 33323511 Free PMC article.
-
Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.J Virol. 2020 Nov 9;94(23):e01185-20. doi: 10.1128/JVI.01185-20. Print 2020 Nov 9. J Virol. 2020. PMID: 32907980 Free PMC article.
-
Natural History of Influenza B Virus-Current Knowledge on Treatment, Resistance and Therapeutic Options.Curr Issues Mol Biol. 2023 Dec 26;46(1):183-199. doi: 10.3390/cimb46010014. Curr Issues Mol Biol. 2023. PMID: 38248316 Free PMC article. Review.
Cited by
-
Estimating Standard-Dose and High-Dose Fluzone Vaccine Efficacies for Influenza A Based on Hemagglutination Inhibition Titers.J Infect Dis. 2025 Jun 2;231(5):1336-1345. doi: 10.1093/infdis/jiae615. J Infect Dis. 2025. PMID: 39670611
-
Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.J Virol. 2024 Oct 22;98(10):e0118624. doi: 10.1128/jvi.01186-24. Epub 2024 Oct 3. J Virol. 2024. PMID: 39360825 Free PMC article.
-
A single residue change only differing by an atomic group can drive imprinting to influenza.Res Sq [Preprint]. 2025 Jul 7:rs.3.rs-6914018. doi: 10.21203/rs.3.rs-6914018/v1. Res Sq. 2025. PMID: 40671817 Free PMC article. Preprint.
-
Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021-2024.Emerg Infect Dis. 2025 Jun;31(6):1202-1206. doi: 10.3201/eid3106.241796. Emerg Infect Dis. 2025. PMID: 40439507 Free PMC article.
-
Immunological imprinting and risks of influenza B virus infection.Nat Immunol. 2024 Aug;25(8):1319-1321. doi: 10.1038/s41590-024-01906-w. Nat Immunol. 2024. PMID: 39030434 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical